PP-084 Early virologic response predicts therapeutic outcomes in adefovir-treated HBeAg-positive chronic hepatitis B (CHB) patients
نویسندگان
چکیده
منابع مشابه
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
BACKGROUND/AIMS We investigated the durability of the biochemical and virologic responses after adefovir (ADV) discontinuation in lamivudine-resistant (LMV-R) chronic hepatitis B (CHB) patients, and the outcomes of ADV discontinuation compared to that of ADV maintenance. METHODS The indication for ADV treatment cessation was an undetectable level of hepatitis B virus (HBV) DNA documented on t...
متن کاملComparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
BACKGROUND Chronic hepatitis B consists of different clinical phases. Laboratory and histological assessments can help differentiate the clinical phases of this disease and thus lead to better management. OBJECTIVES This study was conducted to determine laboratory and histological characteristics of HBeAg-negative and HBeAg-positive chronic hepatitis B patients. PATIENTS AND METHODS In this...
متن کاملStudy on Post-Treatment Relapse in HBeAg Positive CHB Patients.
BACKGROUND Many factors are associated with post-treatment relapse in CHB patients, and there are no effective factors to predict relapse. In this study, we investigate the influence factors associated with post-treatment relapse and their predictive value in HBeAg positive CHB (eP-CHB). METHODS The factors associated with post-treatment relapse were analyzed firstly by a retrospective study ...
متن کاملPegylated Interferon Alfa in HBeAg-positive Chronic Hepatitis B
Background: Treatment with interferon-alfa has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. Aim: To investigate the safety of peginterferon alfa-2b in 300 hepatitis B e antigen-positive patients with compensated liver disease. Methods: Patients were treated with peginterferon al...
متن کاملOn-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B
BACKGROUND & AIMS Virological breakthrough (VBT) could be a manifestation of chronic hepatitis B (CHB) in patients treated with long-term nucleot(s)ide analogues. We aimed to determine the association of on-treatment serum hepatitis B virus (HBV) DNA with VBT in HBeAg-positive CHB patients receiving entecavir (ETV) treatment. METHODS A retrospective cohort study, including 162 consecutive pat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2008
ISSN: 1201-9712
DOI: 10.1016/s1201-9712(09)60235-6